Envuteg 300 mg. 25 mg. 50 mg Tablets
PDF Leaflet Revision Date: 12 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults and children u2265 40 kg.
Dosage (summary)
One tablet once daily orally with or without food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential risk of neural tube defects.
Key Drug Interactions
- Metformin (contraindicated)
- Dofetilide (contraindicated)
- Etravirine (avoid without specific co-administered agents)
Contraindications
- Hypersensitivity to components
- Severe renal impairment
- Severe hepatic impairment
- Pregnancy and lactation
- Patients < 40 kg
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Rash
- Neutropenia
Counselling Points
- Monitor for signs of lactic acidosis.
- Regular liver function tests recommended.
- Use effective contraception in women of childbearing potential.
Serious warnings
- Lactic acidosis
- Severe hepatotoxicity
- Immune Reconstitution Inflammatory Syndrome (IRIS)
Important Disclaimer
The Envuteg 300 mg. 25 mg. 50 mg Tablets professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
